Jesse Swen

Full professor of clinical pharmacy, in particular translational pharmacogenetics

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Biostatistics Biostatistics professors in Netherlands

About

Jesse Swen is a Full Professor of Clinical Pharmacy, specializing in translational pharmacogenetics at the Leiden University Medical Center in the Netherlands. His recent research includes significant contributions to pharmacogenetics with a focus on implementing early screening in pediatric oncology and improving drug metabolism predictions. Additionally, he has worked on guidelines for gene-drug interactions and explored the genetic contributions to drug exposure and allergy implications. His efforts are pivotal in integrating pharmacogenomics into clinical practice.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (17)

Roos van Westrhenen

Visiting Senior Vice Lecturer

King’s College London

UNITED KINGDOM

Jesse Swen

Research Interests

Explore related searches

About

Articles (20)

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)

Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account

The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening – a case-control study

Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer

Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer

Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas

Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.

Dried blood spot LC-MS/MS quantification of voclosporin in renal transplant recipients using volumetric dried blood spot sampling.

Pharmacokinetic profile of irinotecan in patients with chronic kidney disease: Two cases and literature review

UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety

Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine

Genome‐wide Association Study of Methotrexate‐Induced Liver Injury in Rheumatoid Arthritis Patients

The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress

Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters”

Feasibility of Community Pharmacist-Initiated and Point-of-Care CYP2C19 Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Artificial intelligence in pharmacology research and practice

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate

Collaborators (17)

Roos van Westrhenen

Dirk Jan A. R. Moes

Mikko Niemi

Kirsten J. M. Schimmel

Maaike van der Lee

Patrick Souverein

Tessel Rigter

Martina Cornel

Brenda de Winter

J. Wouter Jukema

Bastiaan Tops

Henk-Jan Guchelaar

Li Gong

Hans Gelderblom

Patrick Kemmeren

Teun van Gelder

Espen Molden

Make your next move.